Pelvic Irradiation With Concurrent Chemotherapy Versus Pelvic and Para-Aortic Irradiation for High-Risk Cervical Cancer: An Update of Radiation Therapy Oncology Group Trial (RTOG) 90-01
State University of New York · The University of Texas MD Anderson Cancer Center · +3 more institutions
Abstract
PURPOSE: To report mature results of a randomized trial that compared extended-field radiotherapy (EFRT) versus pelvic radiotherapy with concomitant fluorouracil and cisplatin (CTRT) in women with locoregionally advanced carcinomas of the uterine cervix. PATIENTS AND METHODS: Four hundred three women with cervical cancer were randomly assigned to receive either EFRT or CTRT. Patients were eligible if they had stage IIB to IVA disease, stage IB to IIA disease with a tumor diameter > or = 5 cm, or positive pelvic lymph nodes. Patients were stratified by stage and by method of lymph node evaluation. RESULTS: The median follow-up time for 228 surviving patients was 6.6 years. The overall survival rate for patients…
Citation impact
- FWCI
- 39.60
- Percentile
- 100%
- References
- 19
Authors
9- PJPatricia J. EifelCorresponding
State University of New York, The University of Texas MD Anderson Cancer Center, RTOG Foundation, Mallinckrodt (United States), New York University
- KWKathryn Winter
State University of New York, The University of Texas MD Anderson Cancer Center, RTOG Foundation, Mallinckrodt (United States), New York University
- MMMitchell Morris
State University of New York, The University of Texas MD Anderson Cancer Center, RTOG Foundation, Mallinckrodt (United States), New York University
- CLCharles Levenback
State University of New York, The University of Texas MD Anderson Cancer Center, RTOG Foundation, Mallinckrodt (United States), New York University
- PWPerry W. Grigsby
State University of New York, The University of Texas MD Anderson Cancer Center, RTOG Foundation, Mallinckrodt (United States), New York University
Topics & keywords
- Medicine
- Radiation therapy
- Cervical cancer
- Stage (stratigraphy)
- Concomitant
- Internal medicine
- Chemotherapy
- Survival rate
- Good health and well-being